SCHEMBL3239031

SCHEMBL3239031

COC(=O)c1cc(N)c(C(=O)OC)s1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.54
MAPT P10636 7/20 0.54
NPC1 O15118 4/20 0.54
RAB9A P51151 3/20 0.54
CASP3 P42574 2/20 0.54
SENP8 Q96LD8 2/20 0.54
SENP7 Q9BQF6 2/20 0.54
SENP6 Q9GZR1 2/20 0.54
IKBKB O14920 1/20 0.54
ALDH1A1 P00352 6/20 0.45
OPRD1 P41143 1/20 0.44
HSD17B10 Q99714 5/20 0.44
KMT2A Q03164 3/20 0.44
TSHR P16473 2/20 0.44
HPGD P15428 6/20 0.44
ATM Q13315 3/20 0.44
GLA P06280 2/20 0.44
GAA P10253 2/20 0.44
MEN1 O00255 2/20 0.44
ALOX15 P16050 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12523092 0.91 KDM4E (0.53) KDM4EMAPTNPC1RAB9ACASP3
SCHEMBL4259136 0.86 KDM4E (0.49) KDM4EMAPTNPC1RAB9ACASP3
SCHEMBL166726 0.81 MAPT (0.54) KDM4EMAPTNPC1RAB9ACASP3
SCHEMBL1417353 0.81 CSNK2A2 (0.45) KDM4EMAPTNPC1RAB9ACASP3
SCHEMBL173108 0.80 RAF1 (0.56) KDM4EMAPTNPC1RAB9ACASP3
SCHEMBL4176316 0.80 KDM4E (0.44) KDM4EMAPTNPC1RAB9ACASP3
SCHEMBL24523710 0.79 KDM4E (0.53) KDM4EMAPTNPC1RAB9ACASP3
SCHEMBL5467194 0.79 ABL1 (0.46) KDM4EMAPTNPC1RAB9ACASP3
SCHEMBL102283 0.79 KDM4E (0.53) KDM4EMAPTNPC1RAB9ACASP3
SCHEMBL10566679 0.79 KDM4E (0.60) KDM4EMAPTNPC1RAB9ACASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240132449-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF 1CBIO, INC. 2024-04-25 US disclosed
WO-2024050370-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF 1CBIO, INC. (US) 2024-03-07 WO disclosed
WO-2024050370-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF 1CBIO, INC. (US) 2024-03-07 WO disclosed
WO-2010059555-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2010-05-27 WO disclosed
WO-2010059555-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2010-05-27 WO disclosed
WO-2010022308-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2010-02-25 WO disclosed
WO-2010022308-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132449-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF PARP1, PARP11, PARP12 KDM4E 1701/4885MAPT 4689/4885NPC1 2461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.